

Odelia Cooper

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/457370/publications.pdf>

Version: 2024-02-01

34
papers

1,708
citations

304368

22
h-index

476904

29
g-index

35
all docs

35
docs citations

35
times ranked

1773
citing authors

#	ARTICLE	IF	CITATIONS
1	EGFR as a therapeutic target for human, canine, and mouse ACTH-secreting pituitary adenomas. Journal of Clinical Investigation, 2011, 121, 4712-4721.	3.9	220
2	D-aspartate localizations imply neuronal and neuroendocrine roles. Proceedings of the National Academy of Sciences of the United States of America, 1997, 94, 2013-2018.	3.3	206
3	Human and murine pituitary expression of leukemia inhibitory factor. Novel intrapituitary regulation of adrenocorticotropin hormone synthesis and secretion.. Journal of Clinical Investigation, 1995, 95, 1288-1298.	3.9	129
4	A Structural and Functional Acromegaly Classification. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 122-131.	1.8	97
5	Silent corticotroph adenomas. Pituitary, 2018, 21, 183-193.	1.6	87
6	Single-surgeon fully endoscopic endonasal transsphenoidal surgery: outcomes in three-hundred consecutive cases. Pituitary, 2013, 16, 393-401.	1.6	79
7	Silent Corticogonadotroph Adenomas: Clinical and Cellular Characteristics and Long-Term Outcomes. Hormones and Cancer, 2010, 1, 80-92.	4.9	72
8	Subclinical hyperfunctioning pituitary adenomas: The silent tumors. Best Practice and Research in Clinical Endocrinology and Metabolism, 2012, 26, 447-460.	2.2	70
9	Prolactinoma ErbB receptor expression and targeted therapy for aggressive tumors. Endocrine, 2014, 46, 318-327.	1.1	69
10	Long-Term Endocrine Outcomes Following Endoscopic Endonasal Transsphenoidal Surgery for Acromegaly and Associated Prognostic Factors. Neurosurgery, 2017, 81, 357-366.	0.6	67
11	Opiate Drug Use: A Potential Contributor to the Endocrine and Metabolic Complications in Human Immunodeficiency Virus Disease. Clinical Infectious Diseases, 2003, 37, S132-S136.	2.9	66
12	HER2/ErbB2 Receptor Signaling in Rat and Human Prolactinoma Cells: Strategy for Targeted Prolactinoma Therapy. Molecular Endocrinology, 2011, 25, 92-103.	3.7	64
13	Expression and function of ErbB receptors and ligands in the pituitary. Endocrine-Related Cancer, 2011, 18, R197-R211.	1.6	61
14	Ectopic acromegaly due to growth hormone releasing hormone. Endocrine, 2013, 43, 293-302.	1.1	58
15	Silent corticotroph adenomas. Pituitary, 2015, 18, 225-231.	1.6	58
16	Ovarian hyperstimulation syndrome caused by an FSH-secreting pituitary adenoma. Nature Clinical Practice Endocrinology and Metabolism, 2008, 4, 234-238.	2.9	43
17	EGFR/ErbB2-Targeting Lapatinib Therapy for Aggressive Prolactinomas. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e917-e925.	1.8	37
18	Heregulin Regulates Prolactinoma Gene Expression. Cancer Research, 2009, 69, 4209-4216.	0.4	35

#	ARTICLE	IF	CITATIONS
19	ErbB Receptor-Driven Prolactinomas Respond to Targeted Lapatinib Treatment in Female Transgenic Mice. <i>Endocrinology</i> , 2015, 156, 71-79.	1.4	33
20	Role of tyrosine kinase inhibitors in the treatment of pituitary tumours. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2017, 24, 301-305.	1.2	33
21	Dopamine Agonists for Pituitary Adenomas. <i>Frontiers in Endocrinology</i> , 2018, 9, 469.	1.5	33
22	Bisphosphonate Drug Holiday: Choosing Appropriate Candidates. <i>Current Osteoporosis Reports</i> , 2013, 11, 45-51.	1.5	30
23	Sellar and clival plasmacytomas: case series of 5 patients with systematic review of 65 published cases. <i>Pituitary</i> , 2017, 20, 381-392.	1.6	23
24	Altered Pituitary Gland Structure and Function in Posttraumatic Stress Disorder. <i>Journal of the Endocrine Society</i> , 2017, 1, 577-587.	0.1	15
25	SUN-442 EGFR/ErbB2 Targeted Therapy for Aggressive Prolactinomas. <i>Journal of the Endocrine Society</i> , 2019, 3, .	0.1	8
26	Treatment of Aggressive Pituitary Adenomas: A Case-Based Narrative Review. <i>Frontiers in Endocrinology</i> , 2021, 12, 725014.	1.5	6
27	Editorial: Targeted Therapy for Pituitary Adenomas. <i>Frontiers in Endocrinology</i> , 2019, 10, 358.	1.5	3
28	Pembrolizumab-Induced Diabetic Ketoacidosis: A Review of Critical Care Case. <i>Cureus</i> , 2021, 13, e18983.	0.2	3
29	Dural Invasion as a Marker of Aggressive Pituitary Adenomas. <i>Neurosurgery</i> , 2022, 90, 775-783.	0.6	3
30	HER2/ErbB2 Receptor Signaling in Rat and Human Prolactinoma Cells: Strategy for Targeted Prolactinoma Therapy. <i>Endocrine Reviews</i> , 2010, 31, 943-943.	8.9	0
31	HER2/ErbB2 Receptor Signaling in Rat and Human Prolactinoma Cells: Strategy for Targeted Prolactinoma Therapy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 5457-5457.	1.8	0
32	Hypertension Therapy. , 2013, , 561-575.		0
33	Cabergoline is an effective treatment for clinically non-functioning pituitary adenomas. <i>Endocrine Abstracts</i> , 0, , .	0.0	0
34	SUN-461 Predictors of Early and Late Hyponatremia after Pituitary Surgery. <i>Journal of the Endocrine Society</i> , 2019, 3, .	0.1	0